The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

Multiple therapies currently exist for renal cell carcinoma, however, most do not result in cure and the development of acquired resistance is the rule rather than the exception. CDK4/6 and PIM1 kinases are potential new therapeutic targets in RCC. Abemaciclib is a potent CDK4/6 and PIM1 kinase inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Small, Jeffrey, Washburn, Erik, Millington, Karmaine, Zhu, Junjia, Holder, Sheldon L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707010/
https://www.ncbi.nlm.nih.gov/pubmed/29221116
http://dx.doi.org/10.18632/oncotarget.19618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707010/
https://www.ncbi.nlm.nih.gov/pubmed/29221116
http://dx.doi.org/10.18632/oncotarget.19618

Ejemplares similares